RNA

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer. Amid continued… Read More

#News

#DNA #Gene therapy #Plasmid DNA #RNA

Yapan Bio expands to a new process development facility in India 

Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India, which has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.   The expansion includes three upstream suites (including Bio-Safety Level-2… Read More

#News

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer and reflects… Read More

#News

#Collaboration #CRISPR #CRISPR-Cas9 #Cystic fibrosis #Finance #Gene editing #Liver disease #Neuropsychiatric disorders #Oncology #RNA

This week in drug discovery (10-14 October)

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships… Read More

#News

RNA strand
#Gene therapy #mRNA #R&D #Research & development #RNA

New solution to boost RNA drug development

Benchling has launched its first full set of capabilities for designing, modeling, and studying both natural and chemically modified RNA in a single solution. As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. Following… Read More

#News

#Podcast #RNA #Sustainability

DDW podcast: Improve process while maintaining quality

This is the latest episode of the free DDW podcast, “How to improve process while maintaining quality”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “How can the bioprocess industry respond to cost and maintain quality?” and “RNA:… Read More

#News

#Narrated podcasts #Podcasts #RNA #Sustainability

How to improve process while maintaining quality

This is the latest episode of the free narrated DDW podcast, “How to improve process while maintaining quality”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “How can the bioprocess industry respond to cost and maintain… Read More

#Podcasts

Vaccine
#Lipids #RNA #Vaccines

eTheRNA Manufacturing launches service for RNA vaccines

Specialist RNA process developer eTheRNA Manufacturing has introduced a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.  This new LNP service uses eTheRNA’s proprietary lipid libraries and formulations to facilitate targeted delivery and… Read More

#News

#Antigen #Biotechnology #Immunology / Virology & Vaccines #mRNA #RNA #Therapeutics

What’s next for RNA-based medicine post-Covid-19?

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shares what’s next for RNA-based medicine post-pandemic with DDW. With SARS-CoV-2 circulating the globe and leading to over five million deaths worldwide1, all eyes are on the critical role messenger RNA (mRNA) vaccines are playing in… Read More

#Covid-19 #Exclusive Content #News #Trends & Analysis

#Covid booster #Covid-19 #Immunology / Virology & Vaccines #Omicron #RNA #T-Cells

Early data for multivariant Covid-19 vaccine booster shows promise  

The first results of an early trial of a multivariant Covid-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response.  The results  US-based biotechnology company Gritstone bio, in collaboration with The University of Manchester and Manchester University… Read More

#Covid-19 #News

#Biosciences #Drug development #Funding #RNA #Technology #Therapeutics

Sixfold Bioscience completes $10.5 million seed financing 

Sixfold Bioscience (Sixfold), a company using computation and advanced chemistry to design RNA therapeutic delivery systems, has raised $10.5 million in its seed funding round, which will support the continued development of the company’s Mergo RNA therapeutics delivery platform.  Investors   Investors in the seed round included Cantos… Read More

#Business & Investment #News

#Drug design #Drug development #Immunology / Virology & Vaccines #mRNA #RNA #Synthetic biology

RNA: a coming-of-age technology for viral vaccines 

Listen to this article on the DDW Podcast: Dr Andy Lane, Commercial Director at The Native Antigen Company, discusses the development of a new generation of vaccine platforms that can be rapidly adapted to novel threats on-demand and at low cost.  Vaccines are one of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion

#Clinical trials #Covid-19 #RNA

CV2CoV shows improved immune protection in preclinical study 

CureVac and GSK have published preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates.   The study, conducted in collaboration with Harvard Medical School, assessed cynomolgus macaques vaccinated… Read More

#Covid-19 #News

#Biologics #Biology #Data #Genetics / genomics #RNA #Therapeutics

Starting line: focus on Canadian start-ups

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion #Start-up Zone

#Cancer research #Immunotherapy #Infectious diseases #RNA

eTheRNA immunotherapies opens new office

eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has opened a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong. The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will… Read More

#News

#Covid-19 #Drug development #Drug discovery #Pharmaceuticals #RNA #SARS-CoV-2

SARS-CoV-2 spike protein induces lipid stripping from cell membrane

Scientists at the Institut Laue-Langevin (ILL), in collaboration with the Paul Scherrer Institut (PSI), the Institut de Biologie Structurale (IBS) and the Australian Nuclear Science and Technology Organisation (ANSTO), have published new data on how the SARS-CoV-2 spike protein interacts with mammalian lung cell membranes, allowing the viral… Read More

#Covid-19 #News #Trending News